First Inhaled Powder Launched for Agitation Treatment

First Inhaled Powder Launched for Agitation Treatment
First Inhaled Powder Launched for Agitation Treatment

Teva announced that Adasuve (loxapine) inhalation powder is now available for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

The exact mechanism of action of loxapine, a typical antipsychotic, in the treatment of agitation associated with schizophrenia is unknown. However, its efficacy could be mediated through a combination of antagonism of central dopamine D2 and serotonin 5-HT2A receptors.

RELATED: Psychiatric Disorders Resource Center

Adasuve can cause bronchospasm that can potentially lead to respiratory distress and respiratory arrest. Due to its risk of bronchospasm, Adasuve is only available through a restricted program called the Adasuve REMS Program.  

Adasuve inhalation powder is available in a 10mg dosage strength as a single-use, disposable inhaler in 5-unit cartons.

For more information call (800) 292-4283 or visit Adasuve.com.

Loading links....